Tirzepatide and oral HRT absorption: what the evidence actually shows

What's this video probably claiming?

Based on the caption, Dr. Nighat Arif, a UK-based GP with a significant social media following who often covers women's health topics, is responding to a follower question about whether tirzepatide (Mounjaro) could interfere with oral hormone replacement therapy, specifically progesterone and progestogens used for endometrial protection. The implied claim is that tirzepatide's gastric-emptying delay could reduce or alter the absorption of oral HRT components, potentially leaving the endometrium inadequately protected in women on combined HRT regimens. This is a legitimate clinical concern worth raising, and the framing appears to be cautionary rather than alarmist. The video likely advises women on tirzepatide who take oral progesterone to discuss this interaction with their prescriber. The hashtags confirm this is squarely about GLP-1 pharmacology and gynecological safety, not weight loss promotion.

What does the science actually show?

Tirzepatide is a dual GIP and GLP-1 receptor agonist. Like semaglutide, it slows gastric emptying, though the clinical significance of this effect varies by dose and individual. A 2023 pharmacokinetic study published in Clinical Pharmacokinetics (Bergman et al.) showed that semaglutide reduced the absorption rate of co-administered oral medications, with peak concentration (Cmax) of some drugs reduced by up to 50% and time-to-peak (Tmax) delayed by around 90 minutes. Tirzepatide data are less strong, but mechanistically the pathway is the same. For oral micronised progesterone specifically, which already has notoriously variable bioavailability (roughly 5-10% oral bioavailability per Tavaniotou et al., 2000, European Journal of Obstetrics and Gynecology), any further reduction in absorption rate or peak concentration is a reasonable clinical concern. Whether this translates to actual endometrial harm in practice has not been directly studied in women using both tirzepatide and oral HRT simultaneously.

Where does the social media noise diverge from clinical reality?

The concern itself is scientifically grounded, but the gap between plausible pharmacokinetic theory and demonstrated clinical harm is significant, and this distinction often gets lost in short-form content. Delayed gastric emptying changes absorption rate more than total bioavailability in many cases. For endometrial protection, what matters clinically is whether progesterone levels over time remain sufficient, not just whether Cmax is reduced on any given dose. The MHRA and FDA have not issued formal guidance specifically addressing oral HRT interactions with tirzepatide or semaglutide, which tells you something about where the evidence currently sits. It is also worth noting that switching to transdermal or vaginal progesterone formulations bypasses gastric absorption entirely, making this a readily solvable clinical problem rather than a contraindication. Videos that raise the alarm without mentioning these practical alternatives can leave patients more anxious than informed.

What should you actually know?

If you are taking tirzepatide or semaglutide alongside oral HRT containing progesterone or a progestogen, this is a conversation worth having with your prescriber, not a crisis. Transdermal estrogen is already preferred in many clinical guidelines for women with obesity or cardiovascular risk, and vaginal micronised progesterone (such as Utrogestan used vaginally) is an established alternative that sidesteps gastric absorption entirely. Women on oral contraceptives using GLP-1 agonists have been flagged in product labelling, with the tirzepatide prescribing information recommending a barrier method for four weeks after starting or each dose increase. That principle extends logically to oral HRT, though direct evidence is lacking. The bottom line: the pharmacological concern Dr. Arif is raising is real and under-discussed. The solution is usually a formulation switch, not stopping either medication. Always confirm changes with a qualified clinician.